Skip to main content
TipRanks
Go Ultimate75% OFF

Braveheart Bio, Inc. (BRVE) Financial Statements

23 Followers

Braveheart Bio, Inc. Financial Overview

Braveheart Bio, Inc.'s market cap is currently $1.69B. The company's EPS TTM is $-2.89; its P/E ratio is -6.39; Braveheart Bio, Inc. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25
Income Statement
Total Revenue$ 0.00
Gross Profit$ 0.00
Operating Income$ -66.75M
EBITDA$ -66.75M
Net Income$ -66.75M
Balance Sheet
Cash & Short-Term Investments$ 89.16M
Total Assets$ 89.35M
Total Debt$ 0.00
Net Debt$ -89.16M
Total Liabilities$ 5.33M
Stockholders' Equity$ 84.02M
Cash Flow
Free Cash Flow$ -2.01K
Operating Cash Flow$ -2.01K
Investing Cash Flow$ -33.57K
Financing Cash Flow$ 124.74K

Currency in USD

Braveheart Bio, Inc. Earnings and Revenue History

-75M-50M-25M00 %0.4 %0.8 %1.2 %EarningsProfit Margin2025RevenueEarningsProfit Margin

Braveheart Bio, Inc. Liabilities to Assets

040M80M120M4 %5 %6 %7 %LiabilitiesLiabilities to Assets2025AssetsLiabilitiesLiabilities to Assets

Braveheart Bio, Inc. Cash Flow

-50K050K100K150K2025OperatingInvestingFinancing

Braveheart Bio, Inc. Forecast EPS vs Actual EPS

-4-2024Q2 26Q3 26EPS EstimateBeatMiss